The Food and Drug Administration said it granted accelerated approval to Day One Biopharmaceuticals’ tovorafenib for patients six months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals price target raised to $36 from $32 at JPMorgan
- Day One Biopharmaceuticals trading resumes
- Day One Biopharmaceuticals trading halted, volatility trading pause
- Day One Biopharmaceuticals price target lowered to $33 from $35 at Wedbush
- Day One Biopharmaceuticals price target lowered to $40 from $45 at Piper Sandler
